Circulating tumour DNA as a predictive biomarker for tumour response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer
This is an initial experience from India using liquid biopsy next-generation sequencing (NGS) for dynamic monitoring in immunotherapy-treated patients. A 50% cut-off for response as well as a baseline ctDNA 0f 0.3 ng/microlitre showed a trend for better PFS in these patients. This study highlights the need for serial monitoring. To our knowledge, this is among the first real-world Indian studies validating serial NGS-based ctDNA monitoring in immunotherapy-treated NSCLC. It demonstrates feasibility, predictive value, and real-world applicability in a lower-middle-income context.
Authors
- Sabeena Choudhary
- Anurag Mehta (ORCID: https://orcid.org/0000-0001-6517-3664)
- Vanshika Batra
- Abhinav Dewan (ORCID: https://orcid.org/0000-0002-6468-2640)
- P. Venkataraman (ORCID: https://orcid.org/0000-0002-5192-6511)
- Shrinidhi Nathany (ORCID: https://orcid.org/0000-0001-6006-6309)
- Ullas Batra (ORCID: https://orcid.org/0000-0003-3306-9824)
- Mansi Sharma (ORCID: https://orcid.org/0000-0001-9940-8724)
- Rashi Sachdeva
Institutions
- Shree Guru Gobind Singh Tricentenary University (IN)
- Rajiv Gandhi Cancer Institute and Research Centre (IN)
- Fortis Memorial Research Institute (IN)
Publication Details
- Journal
- Lung India
- Published
- 2025-10-23
- DOI
- https://doi.org/10.4103/lungindia.lungindia_127_25
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb